Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06578741 · ClinicalTrials.gov registry record · NA

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study

A NA study, sponsored by W.L.Gore & Associates.

Active
Registry status
NA
Development phase
310
Enrollment target

NCT06578741 is a NA study that is active but no longer recruiting, run by W.L.Gore & Associates. The registered enrollment target is 310 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06578741, a NA study, is active but no longer recruiting, sponsored by W.L.Gore & Associates.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
310 participants
Enrollment target

Study Summary

This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.

Interventions

  • DEVICE GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)

Trial Details

FieldValue
Enrollment Target 310 participants
Start Date 2024-11-25
Est. Completion 2036-06-01
Phase NA

Sponsor

W.L.Gore & Associates

53 total trials

What the Registry Record Tells You About NCT06578741

The ClinicalTrials.gov registry entry for NCT06578741 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) is the first listed.

NCT06578741 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06578741 about?

NCT06578741 is a clinical study titled "GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study". This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.

What is the current status of trial NCT06578741?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 310 participants. The study started on 2024-11-25. Estimated completion is 2036-06-01.

What interventions are being tested in trial NCT06578741?

The interventions under investigation include: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) (DEVICE).

Who is sponsoring clinical trial NCT06578741?

This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.